Randomized, placebo-controlled study of the efficacy of preoperative somatostatin administration in the prevention of postoperative complications following pancreaticoduodenectomy

Hepato-Gastroenterology

Volumn 60, Issue 123, 2013, Pages 400-405

  Wang, Weiguo ^a   Tian, Bole ^a   Babu, Sah Ram ^a   Zhang, Yi ^a   Yang, Min ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Pancreaticoduodenectomy; Postoperative pancreatic fistula

Indexed keywords

AMYLASE; ANTIEMETIC AGENT; PLACEBO; SOMATOSTATIN;

ABDOMINAL DRAINAGE; ADULT; AGED; AMYLASE BLOOD LEVEL; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOSPITAL COST; HUMAN; INFUSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPERATION DURATION; PANCREAS FISTULA; PANCREATICODUODENECTOMY; PNEUMONIA; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; TREATMENT DURATION; VOMITING;

ADULT; AGED; AMYLASES; BIOLOGICAL MARKERS; BLOOD TRANSFUSION; CHI-SQUARE DISTRIBUTION; CHINA; COSTS AND COST ANALYSIS; DRAINAGE; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; GASTROPARESIS; HOSPITAL COSTS; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; PANCREATIC FISTULA; PANCREATICODUODENECTOMY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; RISK FACTORS; SOMATOSTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879573991     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12669     Document Type: Article

References (31)

1. Whipple AO: A reminiscence: pancreaticduodenectomy. Rev Surg 1963; 20:221-225.
2. Lai ECH, Lau SHY, Lau WY: Measures to prevent pancreatic fistula after pancreatoduodenectomy: a comprehensive review. Arch Surg 2009; 144(11):1074-1080.
3. Paye F: The pancreatic stump after pancreatoduodenectomy: the "Achilles heel" revisited. J Visc Surg 2010; 147(1):e13-20.
4. Brazeau P, Vale W, Burgus R, et al.: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179(68):77-79.
5. Taparel D, Susini C, Esteve JP, et al.: Somatostatin analogs: Correlation of receptor affinity with inhibition of cyclic AMP formation in pancreatic acinar cells. Peptides 1985; 6(1):109-114. (Pubitemid 15111382)
6. Klempa I, Schwedes U, Usadel KH: Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin. Chirurg 1979; 50(7):427-431. (Pubitemid 9224613)
7. Sarr MG: The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg 2003; 196(4):556-564.
8. Yeo CJ, Cameron JL, Lillemoe KD, et al.: Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000; 232(3):419-429.
9. Olsen MF, Wennberg E: Fast-track concepts in major open upper abdominal and thoracoabdominal surgery: a review. World J Surg 2011; 35(12):2586-2593.
10. Beuran M, Iordache FM: Damage control surgery: new concept or reenacting of a classical idea? J Med Life 2008; 1(3):247-253.
11. Frymerman AS, Schuld J, Ziehen P, et al.: Impact of postoperative pancreatic fistula on surgical outcome: the need for a classification-driven risk management. J Gastrointest Surg 2010; 14(4):711-718.
12. Hackert T, Werner J, Büchler MW: Postoperative pancreatic fistula. Surgeon 2011; 9(4):211-217.
13. Nojiri T, Misawa T, Saitoh R, et al.: Technical and mechanical risk factors for postoperative pancreatic fistula in pancreaticojejunostomy. Hepatogastroenterology 2011; 58(109):1368-1371.
14. Bassi C, Dervenis C, Butturini G, et al.: Postoperative pancreatic fistula: An International Study Group (ISGPF] definition. Surgery 2005; 138(1):8-13. (Pubitemid 40933766)
15. Wente MN, Veit JA, Bassi C, et al.: Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 2007; 142(1):20-25. (Pubitemid 47042089)
16. Malleo G, Crippa S, Butturini G, et al.: Delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy: validation of International Study Group of Pancreatic Surgery classification and analysis of risk factors. HPB (Oxford) 2010; 12(9):610-618.
17. Harris AG: Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 1994; 35(3 Suppl):S1-4.
18. Beglinger C, Drewe J: Somatostatin and octreotide: physiological background and pharmacological application. Digestion1999; 60 Suppl 2:2-8. (Pubitemid 29178655)
19. Abraldes JG, Bosch J: Somatostatin and analogues in portal hypertension. Hepatology 2002; 35(6):1305-1312. (Pubitemid 34966884)
20. Jenkins SA, Nott DM, Baxter JN: Fluctuations in the secretion of pancreatic enzymes between consecutive doses of octreotide: implications for the management of fistulae. Eur J Gastroenterol Hepatol 1995; 7(3):255-258.
21. Gouillat C, Chipponi J, Baulieux J, et al.: Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomy. Br J Surg 2001; 88(11):1456-1462. (Pubitemid 32989463)
22. Ramacciato G, Mercantini P, Petrucciani N, et al.: Risk factors of pancreatic fistula after pancreaticoduodenectomy: a collective review. Am Surg 2011; 77(3):257-269.
23. Shan YS, Sy ED, Lin PW: Role of somatostatin in the prevention of pancreatic stump-related morbidity following elective pancreaticoduodenectomy in high-risk patients and elimination of surgeon-related factors: prospective, randomized, controlled trial. World J Surg 2003; 27(6):709-714. (Pubitemid 36961105)
24. Koti RS, Gurusamy KS, Fusai G, et al.: Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. HPB (Oxford) 2010; 12(3):155-165.
25. Wente MN, Shrikhande SV, Müller MW, et al.: Pancreaticojejunostomy versus pancreaticogastrostomy: systematic review and meta-analysis. Am J Surg 2007; 193(2):171-183. (Pubitemid 46107920)
26. Ho LT, Chen RL, Chou TY, et al.: Pharmacokinetics and effects of intravenous infusion of somatostatin in normal subjects - a two-compartment open model. Clin Physiol Biochem 1986; 4(4):257-267. (Pubitemid 16003353)
27. Klempa I, Baca I, Menzel J, et al.: Effect of somatostatin on basal and stimulated exocrine pancreatic secretion after partial duodenopancreatectomy. A clinical experimental study. Chirurg 1991; 62(4):293-299 (In German with English abstract).
28. Okan A, Simsek I, Akpinar H, et al.: Somatostatin and ranitidine in the treatment of non-variceal upper gastrointestinal bleeding: a prospective, randomized, double-blind, controlled study. Hepatogastroenterology 2000; 47(35):1325-1327.
29. Villanueva C, Ortiz J, Miñana J, et al.: Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001; 121(1):110-117. (Pubitemid 32591520)
30. Shan YS, Sy ED, Tsai ML, et al.: Effects of somatostatin prophylaxis after pylorus-preserving pancreaticoduodenectomy: increased delayed gastric emptying and reduced plasma motilin. World J Surg 2005; 29(10):1319-1324. (Pubitemid 41625979)
31. Li-Ling J, Irving M: Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg 2001; 88(2):190-199. (Pubitemid 32142703)